SYRE
Price
$14.91
Change
+$0.69 (+4.85%)
Updated
Apr 24, 04:59 PM (EDT)
Capitalization
899.91M
13 days until earnings call
XBIO
Price
$2.72
Change
+$0.17 (+6.67%)
Updated
Apr 24, 04:47 PM (EDT)
Capitalization
4.16M
Ad is loading...

SYRE vs XBIO

Header iconSYRE vs XBIO Comparison
Open Charts SYRE vs XBIOBanner chart's image
Spyre Therapeutics
Price$14.91
Change+$0.69 (+4.85%)
Volume$15.28K
Capitalization899.91M
Xenetic Biosciences
Price$2.72
Change+$0.17 (+6.67%)
Volume$1.93K
Capitalization4.16M
SYRE vs XBIO Comparison Chart
Loading...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SYRE vs. XBIO commentary
Apr 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SYRE is a Buy and XBIO is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 25, 2025
Stock price -- (SYRE: $14.93 vs. XBIO: $2.69)
Brand notoriety: SYRE and XBIO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SYRE: 133% vs. XBIO: 164%
Market capitalization -- SYRE: $899.91M vs. XBIO: $4.16M
SYRE [@Biotechnology] is valued at $899.91M. XBIO’s [@Biotechnology] market capitalization is $4.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $275.91B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SYRE’s FA Score shows that 0 FA rating(s) are green whileXBIO’s FA Score has 1 green FA rating(s).

  • SYRE’s FA Score: 0 green, 5 red.
  • XBIO’s FA Score: 1 green, 4 red.
According to our system of comparison, XBIO is a better buy in the long-term than SYRE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SYRE’s TA Score shows that 5 TA indicator(s) are bullish while XBIO’s TA Score has 6 bullish TA indicator(s).

  • SYRE’s TA Score: 5 bullish, 3 bearish.
  • XBIO’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, XBIO is a better buy in the short-term than SYRE.

Price Growth

SYRE (@Biotechnology) experienced а +17.84% price change this week, while XBIO (@Biotechnology) price change was +10.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.06%. For the same industry, the average monthly price growth was -5.30%, and the average quarterly price growth was -11.62%.

Reported Earning Dates

SYRE is expected to report earnings on Jul 31, 2025.

XBIO is expected to report earnings on Mar 18, 2025.

Industries' Descriptions

@Biotechnology (+8.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($900M) has a higher market cap than XBIO($4.16M). XBIO YTD gains are higher at: -32.456 vs. SYRE (-35.868). XBIO has higher annual earnings (EBITDA): -4.36M vs. SYRE (-208.57M). SYRE has more cash in the bank: 603M vs. XBIO (6.84M). SYRE has less debt than XBIO: SYRE (0) vs XBIO (153K). XBIO has higher revenues than SYRE: XBIO (2.52M) vs SYRE (0).
SYREXBIOSYRE / XBIO
Capitalization900M4.16M21,655%
EBITDA-208.57M-4.36M4,783%
Gain YTD-35.868-32.456111%
P/E Ratio1.72N/A-
Revenue02.52M-
Total Cash603M6.84M8,816%
Total Debt0153K-
FUNDAMENTALS RATINGS
SYRE vs XBIO: Fundamental Ratings
SYRE
XBIO
OUTLOOK RATING
1..100
87
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
16
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9594
PRICE GROWTH RATING
1..100
9392
P/E GROWTH RATING
1..100
76100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XBIO's Valuation (16) in the Biotechnology industry is somewhat better than the same rating for SYRE (76) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew somewhat faster than SYRE’s over the last 12 months.

XBIO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as SYRE (100) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew similarly to SYRE’s over the last 12 months.

XBIO's SMR Rating (94) in the Biotechnology industry is in the same range as SYRE (95) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew similarly to SYRE’s over the last 12 months.

XBIO's Price Growth Rating (92) in the Biotechnology industry is in the same range as SYRE (93) in the Pharmaceuticals Major industry. This means that XBIO’s stock grew similarly to SYRE’s over the last 12 months.

SYRE's P/E Growth Rating (76) in the Pharmaceuticals Major industry is in the same range as XBIO (100) in the Biotechnology industry. This means that SYRE’s stock grew similarly to XBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SYREXBIO
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 4 days ago
84%
Declines
ODDS (%)
Bearish Trend 9 days ago
90%
Bearish Trend 14 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
82%
View a ticker or compare two or three
Ad is loading...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RLUEX3.550.11
+3.20%
Lazard US Equity Concentrated R6
CIGCX16.730.30
+1.83%
Calamos International Growth C
JDPAX14.79N/A
N/A
Janus Henderson Mid Cap Value A
TGRFX6.65N/A
N/A
Transamerica International Focus R6
FSGGX15.41N/A
N/A
Fidelity Global ex US Index

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with CGON. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then CGON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
+4.99%
CGON - SYRE
53%
Loosely correlated
+3.81%
APGE - SYRE
52%
Loosely correlated
+1.42%
ACLX - SYRE
51%
Loosely correlated
+0.53%
PRME - SYRE
50%
Loosely correlated
-1.69%
IMNM - SYRE
50%
Loosely correlated
+0.24%
More